The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Guidelines for the Safe Administration of High-Dose Interleukin-2
Abstract
High-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8% of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients with metastatic melanoma and renal cell carcinoma. Interleukin-2 administration is associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. This article details practical guidelines for the safe administration of high-dose IL-2.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Changes similar to capillary leak syndrome and anasarca are observed in patients with cancer treated with high-dose interleukin-2.
“changes that are similar to those observed in patients with cancer who are treated with high-dose interleukin-2”
From Cytokine storm (2020) · cites this paper as [10]
Citations
Cites
Atkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 486
The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
Denicoff, K. D., RUBINOW, D. R., PAPA, M. Z., SIMPSON, C., SEIPP, C. A., LOTZE, M. T., Chang, A. E., ROSENSTEIN, D., & Rosenberg, S. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-293 · Cited by 456
Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000) · PubMed · Cited by 441
Kammula, U. S., White, D. E., & Rosenberg, S. A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980815)83:4 · Cited by 200
Interleukin-2: Clinical applications
Atkins, M. B. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33077 · Cited by 156
Krouse, R. S., Royal, R. E., Heywood, G., Weintraub, B. D., White, D. E., Steinberg, S. M., Rosenberg, S. A., & Schwartzentruber, D. J. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199511000-00008 · Cited by 94
Self-citationPockaj, B. A., Yang, J. C., Lotze, M. T., Lange, J. R., Spencer, W. F., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., White, D. E., & Rosenberg, S. A. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00003 · Cited by 70
Self-citationFisher, B., Keenan, A. M., Garra, B. S., Steinberg, S. M., White, D. E., DIBISCEGLIE, A., Hoofnagle, J. H., Yolles, P., Rosenberg, S. A., & Lotze, M. T. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1852 · Cited by 70
Guleria, A. S., Yang, J. C., Topalian, S. L., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2714 · Cited by 67
Bruera, E. D., MacEachern, T., Spachynski, K., LeGatt, D. F., MacDonald, R. N., Babul, N., Harsanyi, Z., & Darke, A. C. (1994) · Cancer · doi:10.1002/1097-0142(19941215)74:12 · Cited by 66
Pockaj, B. A., Topalian, S. L., Steinberg, S. M., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.136 · Cited by 51
Kim, H. W., Rosenberg, S. A., Steinberg, S. M., et al. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199407000-00006 · Cited by 19
Zhu, G.-G., Kauppila, A., Risteli, L., Mäkinen, M., Stenbäck, F., & Risteli, J. (1995) · Cancer · doi:10.1002/1097-0142(19950215)75:4
Flagged first, then by citations
Research works printed but not linked: 2
- Fisher, 2000, Cancer J Sci Am, 6, S55
- Atkins, 2000, Cancer J Sci Am, 6, S11
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Metadata
- Authors
- Schwartzentruber, D. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Schwartzentruber, Douglas J.
- Venue
- Journal of Immunotherapy
- Published
- 2001-07
- Volume
- 24
- Issue
- 4
- Pages
- 287-293
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W1984521423
- Cited by
- 182
- References
- 14
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 2 · 2021: 16 · 2020: 10 · 2019: 4 · 2018: 6 · 2017: 9 · 2016: 7 · 2015: 12 · 2014: 16 · 2013: 8 · 2012: 7
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- high-dose interleukin-2, metastatic melanoma, renal cell carcinoma
- MeSH terms
- Carcinoma, Renal Cell, Drug Administration Schedule, Fluid Therapy, Humans, Hypotension, Interleukin-2, Melanoma, Pleural Effusion, Capillary Leak Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
